Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : Italy's regulator approves conditional use of COVID-19 antibody therapies

02/05/2021 | 01:45pm EDT

MILAN, Feb 5 (Reuters) - Italy's medicines regulator AIFA has given the green light for emergency use of COVID-19 antibody therapies developed by U.S drugmakers Eli Lilly and Regeneron, it said on Friday.

The treatments are aimed at patients with mild to moderate disease who are at risk of their condition worsening, AIFA said.

The regulator's scientific committee said it was appropriate to provide this treatment option, while also pointing out that the data is not yet well developed and there is uncertainty about how much benefit the drugs offer.

"This is a high-risk setting for which no standard treatment with proven efficacy is currently available," AIFA said, noting it was giving approval on extraordinary basis due to the emergency situation.

The EU regulator said on Thursday it was reviewing data on the Eli Lilly and Regeneron antibody therapies.

Regeneron's cocktail of casirivimab and imdevimab was authorised for emergency use in the United States in November, and was given to former U.S. President Donald Trump when he was ill with COVID-19.

Eli Lilly's combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%, data from a late-stage trial showed in January. (Reporting by Emilio Parodi Editing by Frances Kerry)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.60% 250.04 Delayed Quote.47.15%
REGENERON PHARMACEUTICALS -0.43% 589.66 Delayed Quote.22.57%
All news about REGENERON PHARMACEUTICALS
10/26SVB Leerink Adjusts Regeneron Pharmaceuticals' Price Target to $798 from $785, Keeps Ou..
MT
10/25ZAI LAB : Says First Patient Treated in China Portion of Global Study of Odronextamab for ..
MT
10/25REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
10/25SANOFI : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints
MT
10/25SANOFI : Regeneron's Dupixent Improves Swallowing in Late-Stage Study
MT
10/25REGENERON PHARMACEUTICALS : Second Dupixent« (dupilumab) Phase 3 Eosinophilic Esophagitis ..
PR
10/22SANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
10/22REGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
10/22SANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 402 M - -
Net income 2021 7 227 M - -
Net cash 2021 5 424 M - -
P/E ratio 2021 8,95x
Yield 2021 -
Capitalization 61 565 M 61 565 M -
EV / Sales 2021 3,90x
Capi. / Sales 2022 5,05x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 592,15 $
Average target price 682,73 $
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS22.57%61 565
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
VERTEX PHARMACEUTICALS-22.12%47 753
BEIGENE, LTD.48.47%35 804